Heron Therapeuti

Company Profile

Heron Therapeuti had its IPO on 1987-08-26 under the ticker symbol HRTX.

The company operates in the Healthcare sector and Biotechnology industry. Heron Therapeuti has a staff strength of 203 employees.

Stock update

Shares of Heron Therapeuti opened at $1.25 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.23 - $1.34, and closed at $1.32.

This is a +5.6% increase from the previous day's closing price.

A total volume of 889,589 shares were traded at the close of the day’s session.

In the last one week, shares of Heron Therapeuti have slipped by -15.92%.

Heron Therapeuti's Key Ratios

Heron Therapeuti has a market cap of $175.95 million, indicating a price to book ratio of 13.8217 and a price to sales ratio of 3.072.

In the last 12-months Heron Therapeuti’s revenue was $117.96 million with a gross profit of $-50508000 and an EBITDA of $-129349000. The EBITDA ratio measures Heron Therapeuti's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Heron Therapeuti’s operating margin was -112.16% while its return on assets stood at -37.15% with a return of equity of -2408.88%.

In Q2, Heron Therapeuti’s quarterly earnings growth was a positive 0% while revenue growth was a positive 15%.

Heron Therapeuti’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

-0.18

Its diluted EPS in the last 12-months stands at $-1.14 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.18. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Heron Therapeuti’s profitability.

Heron Therapeuti stock is trading at a EV to sales ratio of 3.5255 and a EV to EBITDA ratio of -1.6873. Its price to sales ratio in the trailing 12-months stood at 3.072.

Heron Therapeuti stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$201.22 million

Total Liabilities

$86.72 million

Operating Cash Flow

$13.22 million

Capital Expenditure

$278000

Dividend Payout Ratio

0%

Heron Therapeuti ended 2024 with $201.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $201.22 million while shareholder equity stood at $-39284000.00.

Heron Therapeuti ended 2024 with $0 in deferred long-term liabilities, $86.72 million in other current liabilities, 1199000.00 in common stock, $-1870282000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $13.46 million and cash and short-term investments were $33.24 million. The company’s total short-term debt was $2,580,000 while long-term debt stood at $149.39 million.

Heron Therapeuti’s total current assets stands at $165.28 million while long-term investments were $0 and short-term investments were $19.78 million. Its net receivables were $76.69 million compared to accounts payable of $1.96 million and inventory worth $44.62 million.

In 2024, Heron Therapeuti's operating cash flow was $13.22 million while its capital expenditure stood at $278000.

Comparatively, Heron Therapeuti paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.32

52-Week High

$5.1

52-Week Low

$1.07

Analyst Target Price

$7.3

Heron Therapeuti stock is currently trading at $1.32 per share. It touched a 52-week high of $5.1 and a 52-week low of $5.1. Analysts tracking the stock have a 12-month average target price of $7.3.

Its 50-day moving average was $1.51 and 200-day moving average was $2.04 The short ratio stood at 10.53 indicating a short percent outstanding of 0%.

Around 78.2% of the company’s stock are held by insiders while 9205.1% are held by institutions.